EBS Technologies | Updates

By Team EBS Technologies

Physicians Are Becoming Increasingly Interested in the EBS Technology


Dear Companists,

The crowdfunding campaign provides EBS with the unique opportunity to inform many people from various professions and European regions about our therapy method.

This is great, but what has happened at EBS since the campaign launch?

At the time we launched our crowdfunding campaign, we also launched a PR campaign and increased our media activity. Together with our PR agency, we first contacted the most relevant specialist media in the field of ophthalmology and published an article in each of them.

As a next step, we will inform roughly 120 health departments of, for instance, newspapers, magazines, and online portals. These activities, combined with our crowdfunding campaign, have significantly increased awareness of our company:


  1. More and more physicians from the fields of ophthalmology and neurology have become interested in our therapy method and in its mechanism of action. They have offered us to redirect their patients to our therapy centers or to use our therapy method themselves. This is a huge success for EBS, and it proves that we can attract more physicians and that our therapy method is increasingly accepted in Germany.
  2. Patient organizations are also becoming more and more interested in our technology. For instance, we were allowed to present our system to the German glaucoma self-help association in February.
  3. Compared to the previous year, direct patient contacts have increased significantly. In March 2014, we were contacted by a total of 13 patients, and since the beginning of this year, we have already been approached by 29 patients.


Moreover, the increase in patient inquiries from January to February 2015 was very striking because it took place at the same time as our campaign launch (on 09 February 2015) and clearly underlines the campaign's effect on public awareness.


The above figures do not include any inquiries made directly to therapy centers, but only those by patients who contacted EBS directly; thus the figures only indicate a trend.  


To us, the above news is a great source of motivation, for the more people we reach, the more people we can help through our therapy method.

We will use this great success as a starting point for our future activities, and we would like to thank all of you very much for your support!

Best regards,

The EBS team


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 258,825




3.67 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of EBS Technologies.
Already registered?    Log in